Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 8213 results

  1. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    In development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    In development

  2. Apremilast for treating juvenile psoriatic arthritis in people 5 to 17 years [TSID12089]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]

    Awaiting development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Diclofenac–clotrimazole for Vulvovaginal candidiasis (VVC) [TSID 12053]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    In development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    In development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development